The National Pharmaceutical Pricing Authority (NPPA) has increased the ceiling price of the anti-TB drug Rifampicin through a notification issued here yesterday.
This increase is a consequence of the revised conversion cost and packaging cost (CCPC) norms and the increase in the bulk drug price of rifampicin.The government had recently notified a 4.5 per cent across the board increase in the CCPC norms.
This price increase is likely to affect major companies like Lupin, Novartis, GTBL and Themis labs which produce the drug. Lupin is a market leader in
